Cargando…

Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA

OBJECTIVE: Mucopolysaccharidosis type IIIA (MPSIIIA) caused by recessive SGSH variants results in sulfamidase deficiency, leading to neurocognitive decline and death. No disease‐modifying therapy is available. The AAVance gene therapy trial investigates AAVrh.10 overexpressing human sulfamidase (LYS...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugiani, Marianna, Abbink, Truus E. M., Edridge, Arthur W. D., van der Hoek, Lia, Hillen, Anne E. J., van Til, Niek P., Hu‐A‐Ng, Gino V., Breur, Marjolein, Aiach, Karen, Drevot, Philippe, Hocquemiller, Michaël, Laufer, Ralph, Wijburg, Frits A., van der Knaap, Marjo S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270249/
https://www.ncbi.nlm.nih.gov/pubmed/37165777
http://dx.doi.org/10.1002/acn3.51772
_version_ 1785059293790208000
author Bugiani, Marianna
Abbink, Truus E. M.
Edridge, Arthur W. D.
van der Hoek, Lia
Hillen, Anne E. J.
van Til, Niek P.
Hu‐A‐Ng, Gino V.
Breur, Marjolein
Aiach, Karen
Drevot, Philippe
Hocquemiller, Michaël
Laufer, Ralph
Wijburg, Frits A.
van der Knaap, Marjo S.
author_facet Bugiani, Marianna
Abbink, Truus E. M.
Edridge, Arthur W. D.
van der Hoek, Lia
Hillen, Anne E. J.
van Til, Niek P.
Hu‐A‐Ng, Gino V.
Breur, Marjolein
Aiach, Karen
Drevot, Philippe
Hocquemiller, Michaël
Laufer, Ralph
Wijburg, Frits A.
van der Knaap, Marjo S.
author_sort Bugiani, Marianna
collection PubMed
description OBJECTIVE: Mucopolysaccharidosis type IIIA (MPSIIIA) caused by recessive SGSH variants results in sulfamidase deficiency, leading to neurocognitive decline and death. No disease‐modifying therapy is available. The AAVance gene therapy trial investigates AAVrh.10 overexpressing human sulfamidase (LYS‐SAF302) delivered by intracerebral injection in children with MPSIIIA. Post‐treatment MRI monitoring revealed lesions around injection sites. Investigations were initiated in one patient to determine the cause. METHODS: Clinical and MRI details were reviewed. Stereotactic needle biopsies of a lesion were performed; blood and CSF were sampled. All samples were used for viral studies. Immunohistochemistry, electron microscopy, and transcriptome analysis were performed on brain tissue of the patient and various controls. RESULTS: MRI revealed focal lesions around injection sites with onset from 3 months after therapy, progression until 7 months post therapy with subsequent stabilization and some regression. The patient had transient slight neurological signs and is following near‐normal development. No evidence of viral or immunological/inflammatory cause was found. Immunohistochemistry showed immature oligodendrocytes and astrocytes, oligodendrocyte apoptosis, strong intracellular and extracellular sulfamidase expression and hardly detectable intracellular or extracellular heparan sulfate. No activation of the unfolded protein response was found. INTERPRETATION: Results suggest that intracerebral gene therapy with local sulfamidase overexpression leads to dysfunction of transduced cells close to injection sites, with extracellular spilling of lysosomal enzymes. This alters extracellular matrix composition, depletes heparan sulfate, impairs astrocyte and oligodendrocyte function, and causes cystic white matter degeneration at the site of highest gene expression. The AAVance trial results will reveal the potential benefit–risk ratio of this therapy.
format Online
Article
Text
id pubmed-10270249
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-102702492023-06-16 Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA Bugiani, Marianna Abbink, Truus E. M. Edridge, Arthur W. D. van der Hoek, Lia Hillen, Anne E. J. van Til, Niek P. Hu‐A‐Ng, Gino V. Breur, Marjolein Aiach, Karen Drevot, Philippe Hocquemiller, Michaël Laufer, Ralph Wijburg, Frits A. van der Knaap, Marjo S. Ann Clin Transl Neurol Research Articles OBJECTIVE: Mucopolysaccharidosis type IIIA (MPSIIIA) caused by recessive SGSH variants results in sulfamidase deficiency, leading to neurocognitive decline and death. No disease‐modifying therapy is available. The AAVance gene therapy trial investigates AAVrh.10 overexpressing human sulfamidase (LYS‐SAF302) delivered by intracerebral injection in children with MPSIIIA. Post‐treatment MRI monitoring revealed lesions around injection sites. Investigations were initiated in one patient to determine the cause. METHODS: Clinical and MRI details were reviewed. Stereotactic needle biopsies of a lesion were performed; blood and CSF were sampled. All samples were used for viral studies. Immunohistochemistry, electron microscopy, and transcriptome analysis were performed on brain tissue of the patient and various controls. RESULTS: MRI revealed focal lesions around injection sites with onset from 3 months after therapy, progression until 7 months post therapy with subsequent stabilization and some regression. The patient had transient slight neurological signs and is following near‐normal development. No evidence of viral or immunological/inflammatory cause was found. Immunohistochemistry showed immature oligodendrocytes and astrocytes, oligodendrocyte apoptosis, strong intracellular and extracellular sulfamidase expression and hardly detectable intracellular or extracellular heparan sulfate. No activation of the unfolded protein response was found. INTERPRETATION: Results suggest that intracerebral gene therapy with local sulfamidase overexpression leads to dysfunction of transduced cells close to injection sites, with extracellular spilling of lysosomal enzymes. This alters extracellular matrix composition, depletes heparan sulfate, impairs astrocyte and oligodendrocyte function, and causes cystic white matter degeneration at the site of highest gene expression. The AAVance trial results will reveal the potential benefit–risk ratio of this therapy. John Wiley and Sons Inc. 2023-05-11 /pmc/articles/PMC10270249/ /pubmed/37165777 http://dx.doi.org/10.1002/acn3.51772 Text en © 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Bugiani, Marianna
Abbink, Truus E. M.
Edridge, Arthur W. D.
van der Hoek, Lia
Hillen, Anne E. J.
van Til, Niek P.
Hu‐A‐Ng, Gino V.
Breur, Marjolein
Aiach, Karen
Drevot, Philippe
Hocquemiller, Michaël
Laufer, Ralph
Wijburg, Frits A.
van der Knaap, Marjo S.
Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
title Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
title_full Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
title_fullStr Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
title_full_unstemmed Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
title_short Focal lesions following intracerebral gene therapy for mucopolysaccharidosis IIIA
title_sort focal lesions following intracerebral gene therapy for mucopolysaccharidosis iiia
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10270249/
https://www.ncbi.nlm.nih.gov/pubmed/37165777
http://dx.doi.org/10.1002/acn3.51772
work_keys_str_mv AT bugianimarianna focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT abbinktruusem focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT edridgearthurwd focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT vanderhoeklia focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT hillenanneej focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT vantilniekp focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT huangginov focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT breurmarjolein focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT aiachkaren focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT drevotphilippe focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT hocquemillermichael focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT lauferralph focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT wijburgfritsa focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia
AT vanderknaapmarjos focallesionsfollowingintracerebralgenetherapyformucopolysaccharidosisiiia